BidaskClub upgraded shares of Omnicell (NASDAQ:OMCL) from a strong sell rating to a sell rating in a research report sent to investors on Saturday morning.
Several other brokerages have also recently issued reports on OMCL. Oppenheimer reaffirmed a buy rating and issued a $55.00 target price on shares of Omnicell in a report on Tuesday, December 5th. Cantor Fitzgerald reaffirmed a buy rating and issued a $63.00 target price on shares of Omnicell in a report on Thursday, February 1st. Zacks Investment Research raised shares of Omnicell from a sell rating to a hold rating in a report on Friday, February 2nd. Piper Jaffray Companies lifted their target price on shares of Omnicell from $38.00 to $44.00 and gave the stock a neutral rating in a report on Friday, February 2nd. Finally, Craig Hallum cut shares of Omnicell from a buy rating to a hold rating in a report on Friday, February 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. Omnicell has an average rating of Hold and a consensus target price of $56.14.
OMCL stock opened at $42.15 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.73 and a debt-to-equity ratio of 0.38. The stock has a market cap of $1,634.70, a PE ratio of 82.65, a price-to-earnings-growth ratio of 3.48 and a beta of 0.75. Omnicell has a twelve month low of $38.00 and a twelve month high of $55.40.
In related news, Chairman Randall A. Lipps sold 8,186 shares of the business’s stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $44.21, for a total transaction of $361,903.06. Following the completion of the sale, the chairman now directly owns 224,206 shares in the company, valued at $9,912,147.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gary S. Petersmeyer sold 575 shares of the business’s stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $44.43, for a total transaction of $25,547.25. The disclosure for this sale can be found here. 3.77% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the business. Elkfork Partners LLC bought a new position in shares of Omnicell in the fourth quarter worth approximately $225,000. Xact Kapitalforvaltning AB bought a new position in shares of Omnicell in the fourth quarter worth approximately $244,000. Martin & Co. Inc. TN boosted its position in shares of Omnicell by 7.6% in the fourth quarter. Martin & Co. Inc. TN now owns 65,165 shares of the company’s stock worth $3,161,000 after purchasing an additional 4,600 shares during the period. Pier Capital LLC boosted its position in shares of Omnicell by 9.6% in the fourth quarter. Pier Capital LLC now owns 117,875 shares of the company’s stock worth $5,717,000 after purchasing an additional 10,363 shares during the period. Finally, MetLife Investment Advisors LLC bought a new position in shares of Omnicell in the fourth quarter worth approximately $812,000.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.